Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 30Carcinoma, Renal Cell 17Prostatic Neoplasms 13Carcinoma, Transitional Cell 11Melanoma 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Uterine Cervical Neoplasms 6Kidney Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Urothelial Cancer 2Testicular Neoplasms 2Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma in Situ 2Carcinoma 2

Interventions

rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1MEDI0457 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Canal Carcinoma × durvalumab × Genitourinary × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡